2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes

2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes

Abstract Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease affecting 30% of the world’s population and is often associated with metabolic disorders such as metabolic syndrome, type 2 diabetes (T2D), and cardiovascular disease. This review is...

Full description

Bibliographic Details
Main Authors: Amélio F. Godoy-Matos, Cynthia Melissa Valério, Wellington S. Silva Júnior, João Marcello de Araujo-Neto, Marcello Casaccia Bertoluci
Format: Article
Language:English
Published: BMC 2024-01-01
Series:Diabetology & Metabolic Syndrome
Subjects:
Metabolic dysfunction-associated steatotic liver disease
Fatty liver
Type 2 diabetes
Management
Guidelines
Pioglitazone
Online Access:https://doi.org/10.1186/s13098-024-01259-2

Similar Items

Similar Items